Evaluating New Therapies in HIV: Managed Care

Evaluating New Therapies in HIV: Managed Care

Live Webinar
Date Time
Monday, November 20, 2017 1:00pm to 2:00pm ET Register
Monday, December 4, 2017 12:00pm to 1:00pm ET Register
Faculty

Jeffrey D. Dunn, PharmD, MBA
Vice President, Clinical Strategy and Programs and Industry Relations
MagellanRx Management
Salt Lake City, UT

Laura Kogelman, MD
Associate Professor of Medicine
Director, Infectious Disease Clinic and Travelers Health Clinic
Tufts Medical Center
Boston, Massachusetts 

 

Intended Learners

This activity is designed for pharmacy directors, medical directors, and other decision makers working in managed care organizations.

Learning Objectives

After completing this activity, participants should be able to:

  • Compare newly approved medications to their older counterparts to discuss safety and efficacy of both. 
  • Discuss in-development therapies and fixed-dose combinations, and their role in long-term HIV treatment. 
  • Evaluate shifts in focus in the newly updated HIV treatment guidelines to recognize changes in the HIV treatment population. 
Activity Overview

In order to be eligible for documentation of credit, participants must complete the pre-test, attend the full webinar, complete the 10-question post-test with a score of 70% or better, and complete the evaluation form. After successful completion of the post-test and evaluation form online at www.naccme.com, participants may immediately print their documentation of credit.

There is no fee associated with this activity.

For questions regarding this educational activity, please call 609-371-1137.

ACPE Credit Policy

The certificate is not the official record of your participation in the activity. The official record of credit will be the information in CPE Monitor system.

Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended. The reporting function into CPE Monitor will only be available for 60 days after your completion of the activity.  Under ACPE Policy, NACCME will not be able to report your credit to CPE Monitor after this 60 day period.

Hardware/Software Requirements

The evaluation is accessible after the activity via a PC (Windows 7 or newer) or Mac (Mac OS 10.6 or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. Please direct technical questions to webmaster@naccme.com.

 

Accreditation

  In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME) and DKBmed, LLC. NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Save

CME

NACCME designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE

This continuing nursing education activity awards 1 contact hour.

Provider approved by the California Board of Registered Nursing, Provider #13255 for 1 contact hour.

Nurse practitioners may participate in this educational activity and earn a certificate of completing as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements.

CPE

This activity is approved for 1.0 contact hour (.1 CEU) of continuing pharmacy education (UAN: 0276-9999-17-106-L02-P).

This educational activity is a knowledge-based activity.

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by NACCME may contact the Senior Manager, Accreditation and Compliance, NACCME, in writing at 104 Windsor Center Drive, Suite 200, East Windsor, NJ 08520. The Senior Manager, Accreditation and Compliance will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Senior Director, Accreditation and Compliance, NACCME, may be made for a second level of review.

Independent Clinical Reviewer: Kyle R. Copeland, PharmD, Clinical Specialist Pharmacist, Parkwest Medical Center, Assistant Professor, University of Tennessee College of Pharmacy, Knoxville, Tennessee

Nurse Planner: Susie Seaman, NP, Sharp Rees-Stealy Wound Clinic, San Diego, California

Planning Committee

The planning committee comprises H. Eric Cannon, PharmD, FAMCP, Laura Kogelman, MD; Kyle R. Copeland, PharmD; Susie Seaman, NP; Dean Beals, Rachel Deerr, Stan Pogroszewski, DKBmed; and MaryEllen Fama, Jennifer Ilcyn, Michael Kearney, Randy Robbin, John Savage, and Stephanie Weiss, NACCME.

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

The faculty has reported the following:

Dr. Kogelman: Advisory Board—Gilead Sciences; Speakers' Bureau—Gilead Sciences

Dr. Copeland and Dr. Dunn have disclosed no relevant financial relationships with any commercial interests.

Ms. Seaman: Advisory Board—Mölnlycke

Mr. Beals, Ms. Deerr, Ms. Fama, Ms. Ilcyn, Mr. Kearney, Mr. Pogroszewski, Mr. Robbin, Mr. Savage, and Ms. Weiss have disclosed no relevant financial relationships with any commercial interests.

NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations.

The faculty have disclosed that no off-label/unapproved uses of drugs and/or devises will be discussed in the presentations.

Privacy Policy

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2017 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.

Grant Support

Supported by an educational grant from Gilead Sciences, Inc.